Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	59.76	53.4	65.49	47.64	38.35	62.9
Revenue Growth (YoY)	0.18%	-18.47%	37.48%	24.22%	-39.03%	15.00%
Cost of Revenue	29.9	24.32	22.98	19.59	16.35	10.87
Gross Profit	29.87	29.08	42.51	28.05	22	52.03
Selling, General & Admin	11.68	12.19	14.96	11.71	12.73	11.15
Research & Development	13.56	12.97	17.09	29.35	29.73	38.17
Operating Expenses	25.24	25.16	32.05	41.06	42.46	49.32
Operating Income	4.63	3.92	10.46	-13.01	-20.46	2.71
Interest Expense	-0.68	-1.06	-3.18	-2.53	-7.52	-9.67
Interest & Investment Income	1.3	1.3	1.29	1.15	0.4	0.44
Other Non Operating Income (Expenses)	-0.09	-	-	-	-	-
EBT Excluding Unusual Items	5.16	4.15	8.57	-14.4	-27.58	-6.52
Pretax Income	5.16	4.15	8.57	-14.4	-27.58	-6.52
Income Tax Expense	1.25	1.22	0.25	0.53	-	-
Earnings From Continuing Operations	3.91	2.93	8.31	-14.93	-27.58	-6.52
Net Income	3.91	2.93	8.31	-14.93	-27.58	-6.52
Net Income to Common	3.91	2.93	8.31	-14.93	-27.58	-6.52
Net Income Growth	-42.93%	-64.73%	-	-	-	-
Shares Outstanding (Basic)	73	73	68	48	44	29
Shares Outstanding (Diluted)	82	81	82	48	44	29
Shares Change (YoY)	-5.05%	-1.66%	70.04%	9.81%	51.43%	96.44%
EPS (Basic)	0.05	0.04	0.12	-0.31	-0.62	-0.22
EPS (Diluted)	0.04	0.04	0.09	-0.31	-0.62	-0.22
EPS Growth	-34.17%	-57.71%	-	-	-	-
Free Cash Flow	-1.56	7.39	-2.47	-25.63	-11.74	-26.76
Free Cash Flow Per Share	-0.02	0.09	-0.03	-0.53	-0.27	-0.92
Gross Margin	49.98%	54.46%	64.91%	58.87%	57.37%	82.71%
Operating Margin	7.74%	7.33%	15.97%	-27.32%	-53.36%	4.31%
Profit Margin	6.54%	5.49%	12.69%	-31.33%	-71.92%	-10.37%
Free Cash Flow Margin	-2.61%	13.84%	-3.77%	-53.80%	-30.62%	-42.55%
EBITDA	5.96	5.22	11.65	-11.93	-19.34	4.01
EBITDA Margin	9.97%	9.78%	17.79%	-25.04%	-50.44%	6.38%
D&A For EBITDA	1.33	1.3	1.19	1.09	1.12	1.3
EBIT	4.63	3.92	10.46	-13.01	-20.46	2.71
EBIT Margin	7.74%	7.33%	15.97%	-27.32%	-53.36%	4.31%
Effective Tax Rate	24.19%	29.42%	2.96%	-	-	-
Revenue as Reported	59.76	53.4	65.49	47.64	38.35	62.9

Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q